Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 18 Dec 2020 |
| Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion | 29 Oct 2020 |
| Orion Group Interim Report 1-9/2020 | 21 Oct 2020 |
| Composition of the Nomination Committee of Orion Corporation | 21 Oct 2020 |
| Orion upgrades full-year outlook for 2020 | 19 Oct 2020 |